A new metal compound has been discovered by the researchers from Hong Kong Baptist University, that has the ability to inhibit enzyme actively associated with TNBC (triple negative breast cancer). The enzyme, KDM5A (lysine-specific demethylase 5A) has been inhibited with minimized toxicity in mice.
The compound developed by the team consists of rhodium which potentially and specifically inhibits KDM5A by effectively targeting it, as compared to other inhibitors. Dr. Edmond Ma Dik-lung has said that the presence of KDM5A is more in breast cancer as well as the brain, gastric and lung cancers. It promotes carcinogenesis and creates resistance against drugs. Very limited KDM5A inhibitors are present to date with the current one proving most effective.
The compound works to dismantle interaction between KDM5A and a protein, trimethylated histone H3, which regulates DNA folding. It increases the expression of p27 that diminishes tumor growth by accumulating methylated marks on histone H3. It suppressed the growth of the cells in TNBC cell lines as well. In a vivo mouse model, it exhibited anti-cancer action against TNBC, with less toxicity in vivo as compared to other anti-cancer drugs such as cisplatin and doxorubicin.
Dr. Ma further adds that traditional treatments come with serious side effects along with damage to the organ, not to mention drug resistance. The search for new better treatments is crucial and the metal compound seems to be coming with a promise for better therapy against TNBC.